These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice.
    Author: Chan LN, Zhang S, Cloyd M, Chan TS.
    Journal: Anticancer Res; 1997; 17(1A):499-503. PubMed ID: 9066702.
    Abstract:
    N-(4-Hydroxyphenyl)retinamide (4-HPR), a synthetic retinoic acid derivative, has chemopreventive effects on several types of cancer. We recently showed that 4-HPR is a potent inducer of apoptosis in malignant, but not normal, T-lymphoid cells in vitro. To test 4-HPR's effect in vivo, we used the virus-induced T-lymphoma in AKR/J mice as a model system. The AKR/J mice were fed 4-HPR at 0, 1 or 2 mmole/kg diet, and the animals were monitored as to tumor development, plasma level of 4-HPR, body weight, appetite, and general health. Our results show that in a 19-week period, 4-HPR prevented T-lymphoma development by 40% and 50% of animals fed 1 and 2 mmole 4-HPR/ kg diet, respectively. In the plasma, 4-HPR reached micromolar levels without causing any observable deleterious side-effects. Thus, 4-HPR is potentially useful in chemoprevention of lymphoid cancers.
    [Abstract] [Full Text] [Related] [New Search]